Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BBLGW Stock Summary
In the News
BBLGW Financial details
Company Rating
Sell
Market Cap
1.86M
Income
-9.51M
Revenue
0
Book val./share
5.44
Cash/share
5.67
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-6.14
Forward P/E
-
PEG
0.08
P/S
-
P/B
11.44
P/C
3.03
P/FCF
-0.27
Quick Ratio
3.76
Current Ratio
4.21
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-13.15
EPS next Y
-
EPS next Q
-
EPS this Y
-1958.47%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
375.41%
-
-
-
-
SMA20
216.67%
SMA50
375%
SMA100
533.33%
Inst Own
1.06%
Inst Trans
0.74%
ROA
-142%
ROE
-155%
ROC
-2.52%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
108.87K
Shs Float
100.34K
-
-
-
-
Target Price
-
52W Range
0.019-44.145
52W High
-
52W Low
-
RSI
60
Rel Volume
-
Avg Volume
3.39K
Volume
1
Perf Week
-18.1%
Perf Month
-9.47%
Perf Quarter
68.96%
Perf Half Y
45.52%
-
-
-
-
Beta
0.586
-
-
Volatility
1.64%, 6.81%
Prev Close
0%
Price
17.2
Change
1.53%
BBLGW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -35.23 | -18.8 | -10.64 | 1.83 | -34.01 | |
Operating cash flow per share | -33.45 | -4.4 | -8.12 | -9.37 | -36.32 | |
Free cash flow per share | -33.45 | -4.4 | -8.12 | -9.37 | -36.32 | |
Cash per share | 0.25 | 0 | 44.09 | 19.8 | 11.5 | |
Book value per share | -122.08 | -141.09 | 43.43 | 15.62 | 11.05 | |
Tangible book value per share | -122.08 | -141.09 | 43.43 | 15.62 | 11.05 | |
Share holders equity per share | -122.08 | -141.09 | 43.43 | 15.62 | 11.05 | |
Interest debt per share | 106.41 | 131.08 | 5.32 | -7.78 | 0 | |
Market cap | 283.16M | 282.68M | 128.03M | 19.18M | 1.19M | |
Enterprise value | 294.45M | 294.4M | 121.35M | 11.64M | -1.84M | |
P/E ratio | -82.68 | -154.92 | -79.49 | 27.56 | -0.13 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -87.09 | -662.12 | -104.21 | -5.38 | -0.12 | |
PFCF ratio | -87.09 | -662.12 | -104.21 | -5.38 | -0.12 | |
P/B Ratio | -23.86 | -20.65 | 19.47 | 3.23 | 0.41 | |
PTB ratio | -23.86 | -20.65 | 19.47 | 3.23 | 0.41 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -120.31 | -356.85 | -110.17 | -2.65 | 0.19 | |
EV to operating cash flow | -90.57 | -689.58 | -98.77 | -3.26 | 0.19 | |
EV to free cash flow | -90.57 | -689.58 | -98.77 | -3.26 | 0.19 | |
Earnings yield | -0.01 | -0.01 | -0.01 | 0.04 | -7.52 | |
Free cash flow yield | -0.01 | 0 | -0.01 | -0.19 | -8.03 | |
Debt to equity | -0.95 | -0.86 | 0 | -0.13 | 0 | |
Debt to assets | 367.21 | 0 | 0 | -0.09 | 0 | |
Net debt to EBITDA | -4.62 | -14.21 | 6.06 | 1.71 | 0.32 | |
Current ratio | 0.05 | 0 | 66.81 | 3.33 | 4.5 | |
Interest coverage | 2.51 | -0.83 | -1.37 | 1.68 | 0 | |
Income quality | 0.95 | 0.23 | 0.76 | 2.4 | 1.07 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 311.09 | 244.32 | 101.96 | 25.34 | 91.93 | |
ROIC | 4.47 | 0.42 | -0.17 | 0.33 | -3.24 | |
Return on tangible assets | -111.1 | 0 | -0.24 | 0.08 | -2.39 | |
Graham Net | -122.15 | -141.09 | 43.43 | 13.49 | 8.65 | |
Working capital | -547.62K | -13.69M | 6.58M | 5.95M | 2.91M | |
Tangible asset value | -11.87M | -13.69M | 6.58M | 5.95M | 2.91M | |
Net current asset value | -11.87M | -13.69M | 6.58M | 5.95M | 2.91M | |
Invested capital | -0.95 | -0.86 | 0 | -0.13 | 0 | |
Average receivables | 0 | 0 | 0 | 289.96K | 454.38K | |
Average payables | 84.04K | 254.14K | 282.65K | 50.4K | 180.78K | |
Average inventory | 0 | 0 | 0 | -289.96K | -454.38K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 313.02K | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.29 | 0.13 | -0.24 | 0.12 | -3.08 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 6.3 | -7.95 | -1.69 | -0.61 | -2.9 | |
Operating cash flow per share | -4 | -2.51 | -3.47 | -0.82 | -3.78 | |
Free cash flow per share | -4 | -2.51 | -3.47 | -0.82 | -3.78 | |
Cash per share | 15.45 | 11.52 | 6.69 | 1.42 | 5.67 | |
Book value per share | 12.19 | 5.16 | 5.44 | 1.21 | 5.44 | |
Tangible book value per share | 12.19 | 5.16 | 5.44 | 1.21 | 5.44 | |
Share holders equity per share | 12.19 | 5.16 | 5.44 | 1.21 | 5.44 | |
Interest debt per share | -6.07 | 1.05 | 0 | 0 | 0 | |
Market cap | 24.59M | 33.36M | 11.98M | 17.8M | 2.41M | |
Enterprise value | 17.05M | 27.17M | 4.97M | 13.35M | -611.81K | |
P/E ratio | 2 | -1.95 | -1.69 | -2.32 | -0.39 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -12.6 | -24.71 | -3.3 | -6.97 | -1.2 | |
PFCF ratio | -12.6 | -24.71 | -3.3 | -6.97 | -1.2 | |
P/B Ratio | 4.13 | 12.03 | 2.1 | 4.69 | 0.83 | |
PTB ratio | 4.13 | 12.03 | 2.1 | 4.69 | 0.83 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 19.12 | -10.51 | -1.15 | -6.42 | 0.79 | |
EV to operating cash flow | -8.74 | -20.13 | -1.37 | -5.22 | 0.3 | |
EV to free cash flow | -8.74 | -20.13 | -1.37 | -5.22 | 0.3 | |
Earnings yield | 0.12 | -0.13 | -0.15 | -0.11 | -0.64 | |
Free cash flow yield | -0.08 | -0.04 | -0.3 | -0.14 | -0.84 | |
Debt to equity | -0.13 | 0 | 0 | 0 | 0 | |
Debt to assets | -0.09 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | -8.45 | 2.39 | 1.63 | 2.14 | 3.93 | |
Current ratio | 3.33 | 1.69 | 3.95 | 4.21 | 4.5 | |
Interest coverage | 0.59 | -5.6 | 0 | 0 | 0 | |
Income quality | -2.18 | 0.36 | 2.05 | 1.33 | 1.3 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 41.55 | 30.39 | 14.38 | 4.08 | 18.84 | |
ROIC | -0.86 | -1.31 | -0.53 | -0.55 | -0.4 | |
Return on tangible assets | 0.36 | -0.63 | -0.23 | -0.39 | -0.41 | |
Graham Net | 10.52 | 4.05 | 4.85 | 1.04 | 4.26 | |
Working capital | 5.95M | 2.77M | 5.69M | 3.79M | 2.91M | |
Tangible asset value | 5.95M | 2.77M | 5.69M | 3.79M | 2.91M | |
Net current asset value | 5.95M | 2.77M | 5.69M | 3.79M | 2.91M | |
Invested capital | -0.13 | 0 | 0 | 0 | 0 | |
Average receivables | 289.96K | 289.96K | 0 | 0 | 164.42K | |
Average payables | 843.97K | 1.58M | 1.98M | 1.4M | 731.69K | |
Average inventory | -289.96K | -289.96K | 0 | 0 | -164.42K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.52 | -1.54 | -0.31 | -0.51 | -0.53 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
BBLGW Frequently Asked Questions
What is Bone Biologics Corporation stock symbol ?
Bone Biologics Corporation is a US stock , located in Burlington of Ma and trading under the symbol BBLGW
What is Bone Biologics Corporation stock quote today ?
Bone Biologics Corporation stock price is $17.2 today.
Is Bone Biologics Corporation stock public?
Yes, Bone Biologics Corporation is a publicly traded company.